The asthma therapeutics market in the Asia-Pacific (APAC) region will grow from $3.5 billion to $5.6 billion by 2021, according to business intelligence provider GBI Research.
A rise in disease prevalence rates is responsible for this expansion in the APAC countries, which include China, India, Australia, South Korea and Japan.
Factors behind that rise are identified as aging populations, along with increases in air pollution, dust and pollen levels causing and worsening asthma in children.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze